全反式维甲酸的临床应用及研究进展  

Clinical Application and Research Progress of All-trans-retinoic Acid

作　　者：韦惠琴[1] 钟卫一[1] 

机构地区：[1]广西壮族自治区民族医院血液科,南宁530001

出　　处：《医学综述》2014年第6期1088-1090,共3页Medical Recapitulate

摘　　要：目前,全反式维甲酸(ATRA)是治疗急性早幼粒细胞白血病的临床首选药物。近年来大量研究表明,ATRA能抑制部分致癌基因的活性,诱导肿瘤细胞分化和凋亡,增加癌细胞对化疗药物的敏感性,促进上皮细胞分化与生长,维持上皮组织的正常角化过程,减少皮脂的分泌,具有疗效高、不良反应小等一系列优点。它已成为各种皮肤病、部分恶性血液病、某些肿瘤及血管相关疾病治疗的重要药物之一。All-trans-retinoic acid is currently the preferred treatment of acute promyelocytic leukemia. A large number of recent studies have shown that it can inhibit the activity of some oncogenes, induce tumor cell differentiation and apoptosis, increase the sensitivity of cancer cells to chemotherapeutic drugs, promote epithelial cell differentiation and growth, maintain normal epithelial tissue keratinization process, and reduce sebum secretion, featured with advantages of high efficacy and minor side effects. It has become one of the important drugs for a variety of skin diseases, some hematologic malignancies, some tumors and vascular related diseases.

关 键 词：全反式维甲酸 临床应用 不良反应 

分 类 号：R733[医药卫生—肿瘤]